IP Library Granted Patent US 12,486,524
Granted Patent B2
US 12,486,524 · App. 17/572,978 · Granted Dec 2, 2025

Methods of culturing a mammalian cell

Inventors: Christopher Hwang (Cambridge, MA); Timothy Johnson (Cambridge, MA); Jason Walther (Cambridge, MA); Cheng Cheng (Cambridge, MA); Jonathan Wang (Cambridge, MA); Neha Shah (Cambridge, MA); Seul-A Bae (Cambridge, MA)
Assignee: Genzyme Corporation
C12P21/00C07K16/00C12N5/0043C12N5/005C07K2317/14C12N2500/50C12N2510/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,486,524
App. No.
17/572,978
Granted
Dec 2, 2025
Kind
B2
Abstract

Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.

Claims (12)

1 . A method of culturing a CHO cell in a liquid culture medium to achieve a viable cell density of greater than 60×10 6 cells/mL, the method comprising:

providing a culturing system comprising a vessel, a liquid culture medium disposed within the vessel, and a sparger disposed within the vessel comprising a plurality of pores configured to dispense gas through the sparger into the liquid culture medium; and

perfusion culturing a CHO cell comprising a recombinant protein-encoding nucleic acid in the culturing system comprising the liquid culture medium comprising an amount of poloxamer-188 and antifoam under conditions and a gas flow rate sufficient to produce the recombinant protein in the system, wherein the ratio of antifoam (g/L) to poloxamer-188 (g/L) is about 1.0% to about 3.0% in the liquid culture medium, and wherein:

(i) the plurality of pores are drilled pores with a pore size of 900 μm to 1.1 mm and the poloxamer-188 concentration is 2.5 g/L to 3.1 g/L;

(ii) the plurality of pores are drilled pores with a pore size of 400 μm to 600 μm and the poloxamer-188 concentration is 3.5 g/L to 4.1 g/L;

(iii) the plurality of pores are drilled pores with a pore size of 1 μm to 250 μm and the poloxamer-188 concentration is 4.3 g/L to 8.0 g/L; or

(iv) the plurality of pores are sintered pores with a pore size of 100 μm and the poloxamer-188 concentration is 5.8 g/L, and

wherein the method results in a viable cell density in the liquid culture medium that is greater than 60×10 6 cells/mL.

2 . The method of claim 1 , wherein the plurality of pores are drilled pores with a pore size of 900 μm to 1.1 mm and the poloxamer-188 concentration is 2.5 g/L to 3.1 g/L.

3 . The method of claim 1 , wherein the plurality of pores are drilled pores with a pore size of 1 μm to 250 μm and the poloxamer-188 concentration is 4.3 g/L to 8.0 g/L.

4 . The method of claim 1 , wherein the plurality of pores are drilled pores with a pore size of 400 μm to 600 μm and the poloxamer-188 concentration is 3.5 g/L to 4.1 g/L.

5 . The method of claim 1 , wherein the plurality of pores are sintered pores with a pore size that is 100 μm and the poloxamer-188 concentration is 5.8 g/L.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2022
From: HWANG, CHRISTOPHER; JOHNSON, TIMOTHY; WALTHER, JASON; CHENG, CHENG; WANG, JONATHAN; SHAH, NEHA; BAE, SEUL-A
To: GENZYME CORPORATION
Reel/Frame 059989/0319 →
Continuity (3)
Division 14976486 · Dec 21, 2015
Provisional Application 62095734 · Dec 22, 2014
Related Publication 20220145348A1 · May 12, 2022
References Cited (181)
US 4522811A · Eppestein et al. · 1985 [cited by applicant]
US 5721121A · Etcheverry et al. · 1998 [cited by applicant]
US 6458571B1 · Seiden · 2002 [cited by applicant]
US 6458574B1 · Selden et al. · 2002 [cited by applicant]
US 6974681B1 · McGrew · 2005 [cited by applicant]
US 8765415B2 · Arunakumari · 2014 [cited by examiner]
US 8911964B2 · Pla et al. · 2014 [cited by applicant]
US 9260695B2 · Crowley et al. · 2016 [cited by applicant]
US 11306341B2 · Hwang et al. · 2022 [cited by applicant]
US 11702628B2 · Wang et al. · 2023 [cited by applicant]
US 20030113915A1 · Heidemann et al. · 2003 [cited by applicant]
US 20050186669A1 · Ho et al. · 2005 [cited by applicant]
US 20050272124A1 · Chen et al. · 2005 [cited by applicant]
US 20080199958A1 · Hui · 2008 [cited by applicant]
US 20080206819A1 · Tsao · 2008 [cited by examiner]
US 20090233334A1 · Hildinger et al. · 2009 [cited by applicant]
US 20110020929A1 · Schober et al. · 2011 [cited by applicant]
US 20110053265A1 · Follstad et al. · 2011 [cited by applicant]
US 20120164066A1 · Greene et al. · 2012 [cited by applicant]
US 20140154726A1 · Yang et al. · 2014 [cited by applicant]
US 20140255994A1 · Konstantinov et al. · 2014 [cited by applicant]
US 20140271633A1 · Hossler · 2014 [cited by applicant]
US 20140273206A1 · Jin et al. · 2014 [cited by applicant]
US 20150158907A1 · Zhou et al. · 2015 [cited by applicant]
US 20150183821A1 · Konstantinov et al. · 2015 [cited by applicant]
US 20150202595A1 · Godawat et al. · 2015 [cited by applicant]
US 20150203529A1 · Godawat et al. · 2015 [cited by applicant]
US 20150203531A1 · Godawat et al. · 2015 [cited by applicant]
US 20150203532A1 · Godawat et al. · 2015 [cited by applicant]
US 20150232505A1 · Konstantinov et al. · 2015 [cited by applicant]
US 20150353896A1 · Bruninghaus et al. · 2015 [cited by applicant]
US 20160002594A1 · Yang et al. · 2016 [cited by applicant]
US 20160017280A1 · Villiger-Oberbek et al. · 2016 [cited by applicant]
US 20160017291A1 · Yang et al. · 2016 [cited by applicant]
US 20160177361A1 · Hwang et al. · 2016 [cited by applicant]
US 20190225934A1 · Pla et al. · 2019 [cited by applicant]
US 20220333054A1 · Barrett et al. · 2022 [cited by applicant]
US 20220340948A1 · Coffman et al. · 2022 [cited by applicant]
JP 2011507550 · 2011 [cited by applicant]
JP 2014221765 · 2014 [cited by applicant]
JP 2017519497 · 2017 [cited by applicant]
KR 1020110017233 · 2011 [cited by applicant]
WO WO2002050251 · 2002 [cited by applicant]
WO WO2002101019 · 2002 [cited by applicant]
WO WO2003039459 · 2003 [cited by applicant]
WO WO2006033935 · 2006 [cited by applicant]
WO WO2006138143 · 2006 [cited by applicant]
WO WO2008106515 · 2008 [cited by applicant]
WO WO2009034186 · 2009 [cited by applicant]
WO WO2009061446 · 2009 [cited by applicant]
WO WO2012152945 · 2012 [cited by applicant]
WO WO2013116449 · 2013 [cited by applicant]
WO WO2013151616 · 2013 [cited by applicant]
WO WO2014066519 · 2014 [cited by applicant]
WO WO2014130864 · 2014 [cited by applicant]
WO WO2014130872 · 2014 [cited by applicant]
WO WO2014137903 · 2014 [cited by applicant]
WO WO2014143691 · 2014 [cited by applicant]
WO WO2014151901 · 2014 [cited by applicant]
WO WO2014194137 · 2014 [cited by applicant]
WO WO2014194137A1 · 2014 [cited by examiner]
WO WO2015039115 · 2015 [cited by applicant]
WO WO2015109146 · 2015 [cited by applicant]
WO WO2015109151 · 2015 [cited by applicant]
WO WO2015188009 · 2015 [cited by applicant]
WO WO2015188106 · 2015 [cited by applicant]
WO WO2015191462 · 2015 [cited by applicant]
WO WO2021058713 · 2021 [cited by applicant]
Tordhal et al (“Study of a perfusion process of Chinese hamster ovary cells by ATF filtration in bioreactor ovary cells by ATF filtration in bioreactor,” Sep. 11, pp. 1-47 (Year: 2009). [cited by examiner]
Sandadi et al Bioprocess Biosyst Eng 34:819-832 (Year: 2011). [cited by examiner]
Peng et al Biotechnol. Prog, 30:1411-1418 (Year: 2014). [cited by examiner]
Sieblist et al Biotechnol. Prog., 29:1278-1288 (Year: 2013). [cited by examiner]
Qi et al Lindner-Olsson et al. (eds.), Animal Cell Technology: From Target to Market, 412-415, pp. 412-413 (Year: 2001). [cited by examiner]
Clincke (Biotechnol. Prog., vol. 29, No. 3, 754-767 (Year: 2013). [cited by examiner]
Narayanappa et al Biotechniques, 67 (2), 98-109 (Year: 2019). [cited by examiner]
Tharmalingam Biotechnology & Engineering, 112: 832-837 (Year: 2015). [cited by examiner]
Chalmer et al in ed Al-Rubeai (ed.), Animal Cell Culture, Cell Engineering 9, 163-183 , only 163-180 (Year: 2015). [cited by examiner]
Office Action in Brazilian Patent Application No. BR112017013423-3, dated Sep. 22, 2022, 12 pages (with machine translation). [cited by applicant]
Office Action in Israeli Patent Application No. 253071, dated Apr. 30, 2023, 9 pages (with English translation). [cited by applicant]
Office Action in Russian Patent Application No. 2020101112, dated Jun. 7, 2023, 15 pages (with English translation). [cited by applicant]
Office Action in Brazilian Patent Application No. BR 122022026227.9, dated Mar. 6, 2023, 14 pages (with English machine translation). [cited by applicant]
Office Action in Canadian Patent Application No. 2,971,861, dated Oct. 25, 2022, 3 pages. [cited by applicant]
U.S. Appl. No. 14/061,657, filed Oct. 23, 2013, Yang et al. [cited by applicant]
U.S. Appl. No. 14/769,772, filed Aug. 21, 2015, Yang et al. [cited by applicant]
U.S. Appl. No. 14/769,783, filed Aug. 21, 2015, Jianguo et al. [cited by applicant]
U.S. Appl. No. 14/976,486, filed Dec. 21, 2016, Bae et al. [cited by applicant]
U.S. Appl. No. 62/009,058, filed Jun. 6, 2014, Villiger-Oberbek et al. [cited by applicant]
U.S. Appl. No. 62/095,734, filed Dec. 22, 2014, Bae et al. [cited by applicant]
Australian Office Action in Patent Application No. 2015369809, dated Mar. 15, 2021, 4 pages. [cited by applicant]
Barrett et al., “Microwell engineering characterization for mammalian cell culture process development,” Biotechnol Bioeng., Feb. 1, 2010, 105(2):260-275. [cited by applicant]
Brazilian Office Action in Patent Application No. BR112017013423-3, dated Aug. 25, 2020, 5 pages. [cited by applicant]
Canadian Office Action in Patent Application No. 2,971,861, dated Nov. 2, 2021, 4 pages. [cited by applicant]
Chaturvedi et al., “Comparison of the behavior of CHO cells during cultivation in 24-square deep well microplates and conventional shake flask systems, ” Biotechnology Reports, 2014, 1:22-26. [cited by applicant]
Chinese Office Action in Patent Application No. 201580076640.3, dated Dec. 26, 2019, 8 pages. [cited by applicant]
Chinese Office Action in Patent Application No. 201580076640.3, dated Jan. 21, 2020. [cited by applicant]
Chinese Office Action in Patent Application No. 201580076640.3, dated Jul. 7, 2020, 13 pages. [cited by applicant]
Chinese Office Action in Patent Application No. 201580076640.3, dated Nov. 2, 2020, 11 pages. [cited by applicant]
Clincke et al., “Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor Part I, Effect of the cell density on the process,” Biotechnol. Prog May 2013, 29(3):754-767. [cited by applicant]
Costa et al., “The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody,” Springer Plus, Jan. 28, 2013, 2(25):1-10. [cited by applicant]
Danielson et al., “Maximizing cell densities in miniprep-scale cultures with H15 medium and improved oxygen transfer,” Biochemical Engineering J, 2004, 17:175-180. [cited by applicant]
De Jesus et al., “Tubespin satellites, A fast track approach for process development with animal cells using shaking technology,” Biotechnology and Bioengineering Journal, 2004, 17:217-223. [cited by applicant]
European Communication in Patent Application No. 13786587.9, dated Sep. 27, 2016, 11 pages. [cited by applicant]
European Communication in Patent Application No. 15843061.1, dated Aug. 11, 2017, 2 pages. [cited by applicant]
European Communication in Patent Application No. 15843061.1, dated Jul. 1, 2019, 8 pages. [cited by applicant]
Fernandes-Platzgummer et al., “Scale-up of mouse embryonic stem cell expansion in stirred bioreactors,” American Institute Chemical Engineers, Sep./Oct. 2011, 27(5):1421-1432. [cited by applicant]
Gargi, et al., “Development of a new bioprocess scheme using frozen seed train intermediates to initiate CHO cell culture manufacturing campaigns,” Biotech. Bioeng., May 4, 2013, 110(5):1376-1385. [cited by applicant]
Gebauer et al., “Engineered protein scaffolds as next-generation antibody therapeutics,” Curr Opin Chem Biol., Epub Jun. 6, 2009, 13(3):245-255. [cited by applicant]
Indian Office Action in Patent Application No. 201737025477, dated Nov. 22, 2020, 8 pages. [cited by applicant]
Invitation to Pay in International Application. No. PCT/US2015/034494, dated Aug. 12, 2015, 6 pages. [cited by applicant]
Israel Office Action in Patent Application No. 253071, dated Dec. 17, 2019. [cited by applicant]
Israel Office Action in Patent Application No. 253071, dated Feb. 15, 2021, 10 pages (with English translation). [cited by applicant]
Japanese Office Action in Patent Application No. 2017-533539, dated Feb. 2, 2021, 2 pages. [cited by applicant]
Japanese Office Action in Patent Application No. 2017-533539, dated Jun. 23, 2020, 9 pages. [cited by applicant]
Japanese Office Action in Patent Application No. 2017-533539, dated Nov. 26, 2019, 7 pages. [cited by applicant]
Japanese Office Action in Patent Application No. 2020-177700, dated Nov. 9, 2021, 10 pages (with English translation). [cited by applicant]
Katakam et al., “Effect of Surfactants on the physical stability of recombinant human growth hormone,” Journal of Pharmaceutical Association, Jun. 1, 1995, 84(6):713-716. [cited by applicant]
Kim et al., “Batch, Fed-Batch and Microcarrier Cultures with CHO cell lines in a pressure-cycle driven miniaturized bioreactor,” Biotechnology and Bioengineering, 2011, 109(1):137-145. [cited by applicant]
Mexican Office Action in Patent Application No. MX/a/2017/008338, dated Nov. 24, 2020, 8 pages. [cited by applicant]
Mexican Office Action in Patent Application No. MX/a/2017008338, dated Feb. 25, 2021, 6 pages (with English translation). [cited by applicant]
Nam et al., “The effects of microcarrier culture on recombinant CHO cells under biphasic hypothermic culture conditions,” Cytotechnology, 59(2):81-91, Epub May 2, 2009. [cited by applicant]
Notification of Transmittal of the International Search Report and The Written Opinion issued in PCT/US2013/066410, on Jan. 31, 2014 (12 pages). [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2013/066410, dated May 7, 2015, 8 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2014/017785, dated Sep. 3, 2015, 8 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2014/017803, dated Aug. 25, 2015, 8 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2015/067040, 12 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2014/017785, dated May 20, 2014, 11 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2014/017803, dated May 20, 2014, 11 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2015/034494, dated Nov. 30, 2015, 24 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2015/034709, dated Oct. 30, 2015, 13 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2015/067040, dated Sep. 5, 2016, 19 pages. [cited by applicant]
Peng et al., “Development of small scale cell culture models for screening poloxamer 188 lot-to-lot variation,” Biotechnol Prog, 2014, 30:1411-1418. [cited by applicant]
Pohlscheidt et al., “Optimizing capacity utilization by large scale 3 000 L perfusion in seed train bioreactors,” Biotech. Prog. 29(1): 2220229, Jan. 1, 2012. [cited by applicant]
Rodrigues et al., “Technological progresses in monoclonal antibody production systems,” Biotechnol Prog., Mar.-Apr. 2010, 26(2):332-351. [cited by applicant]
Rosario, “Growth of Mesenchymal Stromal Cells in Automated Microwell Cultures, Influence of the Engineering Environment on Cell Growth Kinetics and Non-Directed Differentiation,” Thesis submitted for the degree of Docto… [cited by applicant]
Russian Office Action in Patent Application No. 2017126045, dated Jun. 24, 2019, 4 pages. [cited by applicant]
Russian Office Action in Patent Application No. 2017126045, dated Nov. 12, 2019, 18 pages. [cited by applicant]
Scott, “Growth of mesenchymal stromal cells in automated microwell cultures: influence of the engineering environment on cell growth kinetics and non-directed differentiation,” (Doctoral dissertation, UCL (University Co… [cited by applicant]
Silk et al., “Fed-batch operation of an industrial cell culture process in shaken microwells,” Biotechnol Lett., 32(1):73-78, print Jan. 2010, Epub Sep. 17, 2009. [cited by applicant]
Singapore Written Opinion in Application No. 11201705103W, dated Dec. 2, 2019, 5 pages. [cited by applicant]
Singapore Written Opinion in Patent Application No. 11201506339R, dated Jul. 21, 2016. [cited by applicant]
Singapore Written Opinion in Patent Application No. 11201506343Q, dated Jun. 27, 2016, 5 pages. [cited by applicant]
Singapore Written Opinion in Patent Application No. 11201705103W, dated May 15, 2018, 7 pages. [cited by applicant]
Smelko et al., “Performance of high intensity fed-batch mammalian cell cultures in disposable bioreactor systems,” Biotechnology Progress, Sep. 2011, 27(5):1358-1364. [cited by applicant]
Strnad et al., “Optimization of cultivation conditions in spin tubes for Chinese hamster ovary cells producing erythropoietin and the comparison of glycosylation patterns in different cultivation vessels,” Biotechnology… [cited by applicant]
Taiwanese Office Action in Patent Application No. 104143177, dated Aug. 24, 2020, 8 pages. [cited by applicant]
Taiwanese Office Action in Patent Application No. 104143177, dated Feb. 22, 2021, 4 pages (with English translation). [cited by applicant]
Taiwanese Office Action in Patent Application No. 104143177, dated Feb. 4, 2020, 7 pages. [cited by applicant]
Taiwanese Office Action in Patent Application No. 104143177, dated Jun. 2, 2021, 6 pages (with English translation). [cited by applicant]
Tao et al., “Development and implementation of a perfusion-based high cell density cell banking process,” Biotechnol. Prog., 2011, 27(3):824-829. [cited by applicant]
Tharmalingam et al., “Evaluating the Impact of High Pluronic F68 Concentrations on Antibody Producing CHO Cell Lines,” Biotechnology and Bioengineering, Apr. 2015, vol. 11, No. 4, 832-837. [cited by applicant]
Tordahl et al., “Study of a perfusion process of Chinese hamster ovary cells by ATF filtration in bioreactor ovary cells by ATF filtration in bioreactor,” Sep. 11, 2009. [cited by applicant]
USPTO Final Office Action issued in U.S. Appl. No. 14/976,486, dated Mar. 29, 2021, 12 pages. [cited by applicant]
USPTO Non-Final Office Action issued in U.S. Appl. No. 14/976,486, dated Sep. 18, 2020, 18 pages. [cited by applicant]
Villiger-Oberbek, Development and application of a high-throughout platform for perfusion-based cell culture processes, Journal of Biotechnology, 212, (2015) pp. 21-29. [cited by applicant]
Wright et al., “A novel seed-train process: using high-density cell banking, a disposable bioreactor, and perfusion technologies,” BioProcessInt., Mar. 10, 2015 Supplement. [cited by applicant]
Yang et al., “Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality,” Biotech. Prog. 30(3): 616-625, May 1, 2014. [cited by applicant]
Zhang et al., “A robust high-throughput sandwich cell-based drug screening platform,” Biomaterials, Feb. 1, 2011, 32(4):1229-124. [cited by applicant]
Zhang et al., “Foaming and media surfactant effects on the cultivation of animal cells in stirred and sparged bioreactors,” J Biotechnology, Dec. 31, 1992, pp. 289-306. [cited by applicant]
Office Action in Israel Patent Application No. 253071, dated Apr. 12, 2022, 5 pages (with English translation). [cited by applicant]
Moretto et al., “Process Raman Spectroscopy for In-Line CHO Cell Culture Monitoring,” American Pharmaceutical Review, Apr. 2011, retrieved on Jun. 16, 2022, retrieved from URL <https://www.americanpharmaceuticalreview.c… [cited by applicant]
Whelan et al., “In situ Raman spectroscopy for simultaneous monitoring of multiple process parameters in mammalian cell culture bioreactors,” Biotechnology Progress, Sep./Oct. 2012, 28(5):1355-1362. [cited by applicant]
Office Action in European Patent Application No. 15843061.1, dated Jun. 22, 2022, 7 pages. [cited by applicant]
Office Action in Japanese Patent Application No. 2022-079207, dated Apr. 25, 2023, 17 pages (with English translation). [cited by applicant]
DeZengotita et al., “Effects of CO2 and osmolality on hybridoma cells: growth, metabolism and monoclonal antibody production,” Cytotechnology, Sep. 1, 1998, 28(1-3):213-227. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2022/024781, mailed on Jul. 11, 2022, 11 pages. [cited by applicant]
Kimura et al., “Effects of elevated pCO2 and/or osmolality on the growth and recombinant tPA production of CHO cells,” Biotechnology and Bioengineering, Oct. 5, 1996, 52(1):152-160. [cited by applicant]
Office Action in Korean Patent Application No. 10-2017-7020466, dated Oct. 31, 2022, 9 pages (with English translation). [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2022/024781, mailed on Oct. 26, 2023, 8 pages. [cited by applicant]
Office Action in Japanese Patent Application No. 2022-079207, dated Oct. 3, 2023, 12 pages (with English translation). [cited by applicant]
Office Action in U.S. Appl. No. 17/721,003, dated Nov. 30, 2023, 14 pages. [cited by applicant]
Office Action in Brazilian Patent Application No. BR122022026227-9, dated Jul. 18, 2023, 8 pages (with English translation). [cited by applicant]
Office Action in Indian Patent Application No. 201737025477, dated Jan. 5, 2024, 9 pages. [cited by applicant]
Office Action in Taiwanese Patent Application No. 110131996, dated Nov. 17, 2023, 12 pages (with English translation). [cited by applicant]
Chisti, “Animal-cell damage in sparged bioreactors,” Trends in Biotechnology, Oct. 1, 2000, 18(10):420-432. [cited by applicant]
Ma et al., “Quantitative studies of cell-bubble interactions and cell damage at different Pluronic F-68 and cell concentrations,” Biotechnology Progress, 2004, 20(4):1183-1191. [cited by applicant]
Michaels et al., “Analysis of cell-to-bubble attachment in sparged bioreactors in the presence of cell-protecting additives,” Biotechnology and Bioengineering, Aug. 20, 1995, 47(4):407-419. [cited by applicant]
Office Action in Israeli Patent Application No. 308064, dated Jun. 5, 2024, 6 pages (with English translation). [cited by applicant]
Office Action in U.S. Appl. No. 17/721,003, dated Jul. 1, 2024, 27 pages. [cited by applicant]
Notice of Allowance in Australian Patent Application No. 2022204152, dated Nov. 12, 2024, 3 pages. [cited by applicant]
Office Action in Australian Patent Application No. 2022204152, dated Aug. 30, 2024, 2 pages. [cited by applicant]
Office Action in Canadian Patent Application No. 3,225,136, dated Jun. 19, 2025, 3 pages. [cited by applicant]